

UDC 616.381-002.1.616.36-008.6-092

https://doi.org/10.33619/2414-2948/108/24

## HEPATIC FAILURE IN PANCREONECROSIS AND THE DEVELOPMENT OF ABDOMINAL SEPSIS

©*Kozhakhmetov S.*, ORCID: 0000-0002-0075-0376, M.D., Astana Medical University, Astana, Kazakhstan

©*Rustemova K.*, ORCID: 0000-0002-8853-9267, SPIN-code: 2236-4076, Dr. habil., Astana Medical University, Astana, Kazakhstan, rustemovak@mail.ru

©*Tsoi O.*, ORCID: 0009-0007-1181-3129, SPIN-code: 7981-5707, National Surgical Center named after M.M. Mamakeev, Astana, Kazakhstan

©*Ashimov Zh.*, ORCID: 0000-0002-3970-8749, SPIN-code: 2430-8820, National Surgical Center named after M.M. Mamakeev, Bishkek, Kyrgyzstan

©*Aknazarov K.*, ORCID: 0000-0003-0365-3405, SPIN-code: 7542-5818, M.D., National Surgical Center named after M.M. Mamakeev, Bishkek, Kyrgyzstan, aknazarov62@mail.ru

©*Zhalgasbaev Zh.*, ORCID: 0000-0001-8270-3014, National Surgical Center named after M.M. Mamakeev, Bishkek, Kyrgyzstan

©*Osmonaliev K.*, ORCID: 0009-0008-4469-1065, SPIN-code: 6374-3222, International AlaToo University, Bishkek, Kyrgyzstan, kudaibergen.osmonaliev@alato.edu.kg

## ПЕЧЕНОЧНАЯ НЕДОСТАТОЧНОСТЬ ПРИ ПАНКРЕОНЕКРОЗЕ И РАЗВИТИИ АБДОМИНАЛЬНОГО СЕПСИСА

©*Кожяхметов С. К.*, ORCID: 0000-0002-0075-0376, канд. мед. наук, Медицинский университет Астана, г. Астана, Казахстан

©*Рустемова К. Р.*, ORCID: 0000-0002-8853-9267, SPIN-код: 2236-4076, д-р мед. наук, Медицинский университет Астана, г. Астана, Казахстан

©*Цой О. Г.*, ORCID: 0009-0007-1181-3129, SPIN-код: 7981-5707, Медицинский университет Астана, г. Астана, Казахстан

©*Ашимов Ж. И.*, ORCID: 0000-0002-3970-8749, SPIN-код: 2430-8820, Национальный хирургический центр им. М.М. Мамакеева, г. Бишкек, Кыргызстан

©*Акназаров К. К.*, ORCID: 0000-0003-0365-3405, SPIN-код: 7542-5818, канд. мед. наук, Национальный хирургический центр им. М.М. Мамакеева, г. Бишкек, Кыргызстан, aknazarov62@mail.ru

©*Жалгасбаев Ж. Г.*, ORCID: 0000-0001-8270-3014, Национальный хирургический центр им. М.М. Мамакеева, г. Бишкек, Кыргызстан

©*Осмоналиев К. Р.*, ORCID: 0009-0008-4469-1065, SPIN-код: 6374-3222, Международный университет АлаТоо, г. Бишкек, Кыргызстан, kudaibergen.osmonaliev@alato.edu.kg

*Abstract.* It is well known that acute destructive pancreatitis, pancreonecrosis is accompanied by severe endogenous intoxication, often leading to the development of multiple organ failure syndrome, liver failure is one of the important links in this process. The mortality rate of patients with pancreonecrosis related to liver failure is as high as 83%, and approximately 5% of patients with pancreonecrosis have fulminant liver failure. Proven: liver function is closely related to the progression of purulent-necrotic complications in patients with acute destructive pancreonecrosis. The authors present the data of literature on the importance of liver failure in the course and prognosis of acute destructive pancreatitis. The pathogenetic role of lipid peroxidation processes are especially emphasized. The controversial issues of portal and systemic bacteremia and toxemia in the development of pancreatogenic abdominal sepsis are discussed, as well as the involvement of the lymphatic system. The authors' research aims to analytically dissect and summarize

the processes underlying the clinical manifestations of liver failure in pancreatic necrosis and their underlying mechanisms, which may provide new insights for further understanding and better management of liver failure in patients with pancreatic necrosis and abdominal sepsis.

*Аннотация.* Известно, что острый деструктивный панкреатит, панкреонекроз сопровождается тяжелой эндогенной интоксикацией, часто приводящей к развитию синдрома полиорганной недостаточности; печеночная недостаточность является одним из важных звеньев этого процесса. Летальность больных панкреонекрозом, связанная с печеночной недостаточностью, достигает 83%, а примерно у 5% больных панкреонекрозом наблюдается фульминантная печеночная недостаточность. Доказано: функция печени тесно связана с прогрессированием гнойно-некротических осложнений у больных острым деструктивным панкреонекрозом. Авторы приводят данные литературы о значении печеночной недостаточности в течение и прогнозе острого деструктивного панкреатита. Особо подчеркивается патогенетическая роль процессов перекисного окисления липидов. Обсуждаются спорные вопросы портальной и системной бактериемии и токсемии в развитии панкреатогенного абдоминального сепсиса, а также участие лимфатической системы.

*Keywords:* acute destructive pancreatitis, liver failure, lipid peroxidation, kallikrein-kinin system, endogenous intoxication, bacteremia.

*Ключевые слова:* острый деструктивный панкреатит, перекисное окисление липидов, калликреин-кининовая система, эндогенная интоксикация, бактериемия.

According to modern concepts, severe purulent-necrotic forms of acute destructive pancreatitis (hereinafter referred to as ADP), including secondary purulent pancreatogenic peritonitis, retroperitoneal pancreonecrosis, septic phlegmon and retroperitoneal abscesses, are qualified as abdominal sepsis (AS) with multiple organ dysfunction syndrome (MODS) and septic shock [1].

In ADP in the reactive phase of the disease, the outcome depends on the accession of infection and the development of various purulent complications up to sepsis [2-4], which is observed in 40-70% of cases, and mortality is 70-85% [3-8].

The spread of the purulent process to the retroperitoneal fibre significantly aggravates the course of the disease and increases mortality from pancreatic shock and purulent-septic complications [9]. However, the main cause of mortality in this case is dysfunction of one or more organs/systems [4, 10, 11] due to the development of abdominal sepsis [12, 13].

There are review articles on the significance of liver failure in ADP and its significance in increasing the severity of the disease and mortality [14, 77], pancreonecrosis in 41.5% [7].

It is the cause of death in 40% of cases, and in destructive forms - in 90-95.2% [19-21, 69, 78]. In ADP, extra-organ complications are present in 60-95% of patients [15, 16]. Therefore, the study of mechanisms of liver failure development in destructive forms of pancreatitis, their role in the development of abdominal sepsis is an urgent task for surgeons.

*Purpose of the study:* to investigate and summarise the results of researchers for the last 10 years, devoted to the search and study of the pathogenesis of liver failure development in patients with destructive form of pancreatitis (pancreonecrosis).

*Search Strategy of the study:* we conducted a review of scientific papers of researchers for the last 10 years, using search resources of publications from journals in Europe, Canada and the USA (PubMed, Medline, Scopus, as well as CIS and RK countries).

*Influence of liver failure in acute destructive pancreatitis and its significance in increasing the severity of the disease and lethality:* the characteristic feature of acute ADP is a high level of endogenous intoxication almost immediately during the transformation of acute pancreatic oedema into haemorrhagic/fatty pancreonecrosis [22, 23], in the structure of which the liver is present in 56.1% of cases [24, 25] and largely determines its severity [26-28].

In ADP, like pancreatogenic shock, MODS is formed during the first week of the disease (enzymatic phase) against the background of severe intoxication and marked haemodynamic disorders [29].

In acute destructive pancreatitis (ADP) the frequency of functional liver failure ranges from 18% to 83.9% [30-32] and is the main cause of death in 12.6-40% of cases [17-20].

According to the data of S. A. Alekseev et al. [33], based on 89 autopsies of persons who died from acute destructive pancreatitis, in 52.8% of cases there was hepatic failure with outcome in hepatorenal syndrome. In pancreonecrosis, the onset and development of acute HF often predetermines the severe course and prognosis of the disease, since it is the liver that is the first and the main barrier to the toxins coming through the portal vein from the pancreas and from the peritoneal cavity [34, 35].

*The role of activation of lipid peroxidation (hereinafter referred to as LPO):* endogenous intoxication is of a specific nature in ADP due to the fact that in the tissues of the pancreas, due to marked alteration and predominance of catabolic processes, there is a decompensation of regulatory systems with the accumulation of high concentrations of effector products. The amount of proelastase decreases, histamine, phospholipases are released in the presence of kallikrein and bile acids (in cholangiogenic pancreatitis), bradykinin and kallidin release occurs under the action of pancreatic kallikrein. The pathogenesis of liver cell damage is based on the activation of lipid peroxidation processes, electrolyte balance disorders, cascade enhancement of fat-dependent processes with the inability of cells to compensate for the necessary energy expenditure [25, 36].

In infected pancreonecrosis (abdominal sepsis), increasing metabolic disorders are accompanied by hypoalbuminemia, increased intoxication, immune system depression and bacteraemia [2, 3, 68].

Damaging factors alter cell membranes with disruption of intracellular homeostasis and release of toxic products of incomplete and perverted metabolism with their entry into the interstitial space and blood [38, 39].

The amount of proelastase decreases, histamine and phospholipases are released in the presence of kallikrein and bile acids (in cholangiogenic pancreatitis), bradykinin and kallidin are released under the action of pancreatic kallikrein. Most authors believe that in pancreonecrosis activated pancreatic and lysosomal enzymes, biologically active substances, toxic decay products of pancreatic tissues at necrobiosis and activation of the kallikrein-kinin system enter the liver via the portal vein [25, 37, 41]; the result is hepatic failure. Although, V.S. Tarasenko et al. [42] indicate that in acute pancreatitis, exo- and endotoxins from the systemic circulation enter the liver. According to A. N. Plekhanov and D. N. Reshetnikov [19], significant changes in destructive pancreatitis occur in porto-hepatic haemodynamics. This is manifested by a reliable decrease in the diameter of the portal vein and linear velocity and volume blood flow in it. Similar data are established in relation to the superior mesenteric vein, whereas the volume blood flow in the hepatic artery does not significantly change. Moreover, the degree of reduction of porto-hepatic haemodynamics was in direct correlation with the severity of PH.

*Cytokine and inflammatory cascade, inflammatory mediators:* as a result of increasing endotoxiosis and direct action of toxins already at early stages of disease development they interact with endothelial cells of hepatic sinusoids and lead to a decrease in blood flow due to pre-capillary

contraction due to increased production of alpha-actin by smooth muscle cells [44-46] microcirculatory disorders occur [47, 48, 72, 73].

At the same time, the production of pro-inflammatory cytokines increases, capable of releasing a large amount of  $H_2O_2$  and active oxygen radicals. The latter, acting on the cell membranes of hepatocytes, disrupt their integrity, i.e. have a cytolytic effect. In addition, the activating effect of cytokines leads to an increase in the procoagulant activity of the endothelium and intravascular hypercoagulation with aggravation of intrahepatic haemodynamic disorders [49]. According to V.S. Tarasenko et al. [42]: this subtle regulatory mechanism is aimed at temporary isolation of the liver parenchyma from the extraordinary stimulus. However, the state of hypertonus, which probably takes place in pancreonecrosis, from protective can become the basis for the development of pathological process as a result of ischaemia and hypoxia.

Studies of a number of authors testify: during the period of functional insufficiency of parenchymatous organs final and intermediate products of catabolism and other substances of toxic action accumulate. There is a disorder of macro- and microcirculation, which leads to a violation of virtually all types of metabolism: carbohydrate, fat, water-electrolyte, bile formation, protein-synthetic, detoxification, haemostatic. As well as reticulo-endothelial system, endocrine metabolism, immunological, etc. [43, 50], which leads to a sharp disturbance of blood circulation, hypoxia and morphological changes in the liver [42, 51].

*Microcirculation disorders of the liver and pancreas:* research results proved that gross microcirculatory disorders occur as a result of a decrease in the linear velocity of blood flow in capillaries, disturbance of blood rheological properties due to the aggregation of formate elements and platelets, thrombosis and haemocoagulation, the consequence of which is initially circulatory and then circulatory-metabolic hypoxia [35,52] with activation of lipid peroxidation (LPO) [53,].

Lefkowitz J. H., Saveliev V. S. in their works proved that as the inflammatory-destructive process in the PG progresses with the formation of necrotic and purulent forms, the second stage of intoxication development begins with the appearance in blood and lymph, mainly products of proteolytic and lipolytic necrosis. In the period of haemodynamic disorders (enzymatic phase), the main pathogenetic mechanisms are enzymeemia, activation of the kallikrein-kinin system and arachidonic acid cascade with the formation of prostaglandins and leukotrienes. A pronounced endotoxemia syndrome - pancreatogenic toxemia syndrome is formed [54].

There is an "evasion" of toxins into the portal vein tributaries into the blood and lymphatic vessels [54-56].

Thus, multicomponent pancreatogenic toxemia, in the path of which the liver is the first target, is carried out due to highly toxic and aggressive pancreatic and lysosomal enzymes, biologically active substances, and decay products of PU tissues as a result of necrobiosis and activation of the kallikreinkin system [15, 57, 58]. In half of the cases of PU develops against the background of functional inferiority of the liver. Endogenous intoxication, microcirculation disorders, decreased linear blood flow velocity in capillaries, deterioration of blood rheological properties, as well as sharp activation of catabolic processes increase tissue oxygen demand, which leads to the development of circulatory-metabolic hypoxia and intensification of lipid peroxidation processes not only in the liver, which is very sensitive to all types of hypoxia [59, 60], but also in all parenchymatous organs [18, 48, 52]. In this case, a significant role belongs to the sharply increased activity of the kallikreinkin system in blood and lymph [52, 54, 61].

The lymphatic hypertension observed in this case increases the concentration of toxic products and protease activity in lymph [50].

There is an insufficiency of compensatory capabilities of the antioxidant system in the liver as a result of its degeneration, which leads to an increase in necrotic processes with the development

of acute liver failure [15, 62, 71]. Steadily increasing endotoxaemia is accompanied by disturbances of macro- and microdynamics not only in PD itself, but also in the whole organism [18, 48], as it is believed to be a result of sharply increased activity of the kallikrein-kinin system in blood and lymph [52, 54, 61].

### *Discussion*

Thus, the leading mechanisms of functional liver disorders in acute pancreatitis are deep microcirculatory disorders, degenerative-dystrophic changes of hepatocytes and decompensation of reparative capabilities. There is purulent and putrefactive decay of the liver and adjacent retroperitoneal fibre with formation of phlegmon and abscesses.

So according to A. N. Plekhanov and D. N. Reshetnikov [19], the clinical and biochemical syndrome of PN includes: frequent hyperbilirubinaemia, increased activity of cytolytic enzymes, discoordination of carbohydrate and protein metabolism. Patients have jaundice (in 100% of cases), skin itching (in 43,3%), hepatosplenomegaly (in 41,6%), hepato-cerebral syndrome (in 5%). Diagnosis of PN is based on biochemical indicators of cytolysis (ALT, AST, LDH), cholestasis (bilirubin, alkaline phosphatase), synthetic liver function (total protein, albumin, triglycerides) [37, 40, 41].

However, according to M.A. Nartaylakov et al. [7], in infected pancreonecrosis there is a pronounced hypercatabolism syndrome, so the level of total protein and its fractions in blood serum is not an adequate marker of acute PN. In addition, in some patients laboratory indicators of cytolysis can remain above normal values for a long time - up to a month. In this regard, the authors, as well as other researchers [27, 37, 74.], consider the concentrations of total bilirubin, alkaline phosphatase and triglycerides in serum to be the most reliable.

According to V. I. Filin [63], in experimental acute haemorrhagic pancreatitis in the first 6-12 hours in the liver tissue there is irregular hemorrhage with congestion in some lobules, focal necroses around vessels, in some places focal destruction of cells with pronounced discomplexity. Already at early stages in patients with acute pancreatitis there are changes in the histological structure of the liver (hepatocytes and reticuloendothelial elements) - morphological picture of acute hepatitis [22, 30, 42, 54, 64].

Apoptosis of hepatocytes is observed. As a number of studies have shown - it is also one of the factors leading to liver failure [75, 76].

It is worth agreeing with the opinion of a number of authors: apoptosis is observed in the endoplasmic reticulum (ER) in cells. The endoplasmic reticulum is the largest membrane organelle in the cell and it controls the processing, modification and synthesis of a large number of proteins in the cell. When the environment in the ER, which is characterised by oxidation and high calcium concentration in severe endotoxemia, it breaks down - this leads to the accumulation of misfolded proteins in the ER, resulting in severe ER stress. In patients who died as a result of acute pancreonecrosis at microscopy of liver tissue, dystrophic and degenerative changes (toxic fatty, protein, granular dystrophy), foci of necrobiosis and necrosis, infarcts are often found [22, 54, 63]. According to S. A. Alekseev et al. [33], there is edema of the interstitial space of hepatocytes (in 76.6% of cases), lymphoid-neutrophil infiltration of portal tracts (65.9%), centrilobular necrosis of hepatocytes (75.7%), microcirculatory channel disorder (75%). All dystrophic and degenerative changes of hepatocytes in pancreonecrosis are associated with massive apoptosis processes. Toxic damage to organs/systems (liver, kidneys, adrenal cortex, as well as nervous, cardiovascular, respiratory and immune systems) forms the MOD syndrome [17, 23, 50, 63, 65, 66].

In general, extra-organ complications in patients with DLD occur in 60.8-96.5% of cases [39, 54, 67, 70].

Summarizing the research results, we can highlight the following points in the pathogenesis of the development of liver failure in abdominal sepsis:

1. Activation of lipid peroxidation processes plays an important role in the development of functional and structural disorders of pancreatocytes and the organism as a whole. The level of antioxidant activity of pancreas tissue is one of the lowest in the organism.

2. Functional liver failure significantly aggravates the course of acute pancreatitis and worsens the prognosis of the disease.

3. Excessive intensification of lipoperoxidation processes is an important pathogenetic link in the mechanism of damage to cell membranes and lysosomal structures in the development of cytolysis, which determines the severity of destruction in the liver.

4. In infected pancreonecrosis, abscesses and septic retroperitoneal phlegmon, i.e. complicated acute destructive peritonitis or abdominal sepsis, acute liver failure is accompanied by immune system depression, so-called secondary sepsis-induced immunodeficiency and bacteraemia.

5. Moreover, systemic toxemia and bacteraemia may occur earlier or simultaneously with the breakthrough of the protective hepatic barrier, located on the path of microorganisms and their toxins to the liver via the portal vein. Since from the retroperitoneum resorption of infected and toxic exudate occurs in the retroperitoneal veins, which are tributaries of the inferior vena cava (lumbar, lower diaphragmatic veins, etc.) or superior vena cava (unpaired and semi-unpaired veins). In addition, in secondary purulent pancreatogenic disseminated peritonitis, everything that is absorbed into the blood vasculature by the parietal peritoneum is also transported into the systemic venous channel, bypassing the v. hornblende. Lymphatic vessels, which in the parietal peritoneum are located closer to the surface than blood vessels and perform purely drainage function. Lymph passing through the lymph nodes eventually flows into the thoracic duct and then into the left venous angle.

#### *Main results*

1. Activation of lipid peroxidation processes plays an important role in the development of functional and structural disorders of pancreatocytes and the organism as a whole. The level of antioxidant activity of pancreas tissue is one of the lowest in the organism.

2. Functional liver failure significantly aggravates the course of acute pancreatitis and worsens the prognosis of the disease.

3. Excessive intensification of lipoperoxidation processes is an important pathogenetic link in the mechanism of damage to cell membranes and lysosomal structures in the development of cytolysis, which determines the severity of destruction in the liver.

4. In infected pancreonecrosis, abscesses and septic retroperitoneal phlegmon, i.e. complicated acute destructive peritonitis or abdominal sepsis, acute liver failure is accompanied by immune system depression, so-called secondary sepsis-induced immunodeficiency and bacteraemia.

5. Moreover, systemic toxemia and bacteraemia may occur earlier or simultaneously with the breakthrough of the protective hepatic barrier, located on the path of microorganisms and their toxins to the liver via the portal vein. Since from the retroperitoneum resorption of infected and toxic exudate occurs in the retroperitoneal veins, which are tributaries of the inferior vena cava (lumbar, lower diaphragmatic veins, etc.) or superior vena cava (unpaired and semi-unpaired veins). In addition, in secondary purulent pancreatogenic disseminated peritonitis, everything that is absorbed into the blood vasculature by the parietal peritoneum is also transported into the systemic venous channel, bypassing the v. hornblende. Lymphatic vessels, which in the parietal peritoneum are located closer to the surface than blood vessels and perform purely drainage function. Lymph passing through the lymph nodes eventually flows into the thoracic duct and then into the left venous angle.

### Conclusion

In acute purulent-necrotic destructive pancreatitis acute liver failure is an integral component of the multi-organ failure syndrome that develops to severe abdominal sepsis.

### References:

1. Gel'fand, B. R., Filimonov, M. I., & Burnevich, S. Z. (1998). Abdominal'nyi sepsis. *Russkii meditsinskii zhurnal*, 11, 3. (in Russian).
2. Howes, N., Greenhalf, W., Rutherford, S., O'Donnell, M., Mountford, R., Ellis, I., ... & Neoptolemos, J. P. (2001). A new polymorphism for the RI22H mutation in hereditary pancreatitis. *Gut*, 48(2), 247-250. <https://doi.org/10.1136/gut.48.2.247>
3. Werner, J., Hartwig, W., Uhl, W., Müller, C., & Büchler, M. W. (2003). Useful markers for predicting severity and monitoring progression of acute pancreatitis. *Pancreatology*, 3(2), 115-127. <https://doi.org/10.1159/000070079>
4. Shugaev, A. I., Gera, I. N., Mosoyan, S. S., Aliev, A. Ya., & Papsheva, V. V. (2009). Faktory, opredelyayushchie razvitie gnoinykh oslozhnenii ostrogo pankreatita v reaktivnoi faze. *Vestnik khirurgii imeni II Grekova*, 168(1), 54-56. (in Russian).
5. Savel'ev, V. S., Filimonov, M. I., Gel'fand, B. R., & Burnevich, S. Z. (2001). Destruktivnyi pankreatit: algoritm diagnostiki i lecheniya. *Consilium medicum*, 3(6), 273-279. (in Russian).
6. Gal'perin, E. I., & Dyuzheva, T. G. (2007). Pankreonekroz: neispol'zovannye rezervy lecheniya (Diskussionnye voprosy k kruglomu stolu). *Annaly khirurgicheskoi gepatologii*, 12(2), 46-51. (in Russian).
7. Nartailakov, M. A., Gvozdik, T. P., Tkachenko, V. N., & Kononov, V. S. (2010). Korrektsiya pechenochnoi nedostatochnosti v kompleksnom lechenii bol'nykh s infitsirovannym pankreonekrozom. *Meditsinskii vestnik Bashkortostana*, 5(5), 6-10. (in Russian).
8. Propp, A. R., Poluektov, V. L., Lobanov, V. G., Arestovich, R. A., Prankevich, N. N., Astankov, R. A., & Kuz'menko, V. V. (2011). Tekhnicheskie resheniya pri ustranении protokovoi gipertenzii podzheludochnoi zhelezy. *Khirurgiya. Zhurnal im. NI Pirogova*, (6), 32-37. (in Russian).
9. Timerbulatov, V. M., Mustafin, T. I., Timerbulatov, M. V., & Imaeva, A. K. (2008). Sravnitel'nyi analiz ball'noi otsenki tyazhesti ostrogo pankreatita. *Vestnik khirurgii imeni II Grekova*, 167(2), 79-81. (in Russian).
10. Gel'fand, E. B., Gologorskii, V. A., & Gel'fand, B. R. (2000). Klinicheskaya kharakteristika abdominal'nogo sepsisa u khirurgicheskikh bol'nykh. *Infektsii i antimikrobnaya terapiya*, 1(1), 6. (in Russian).
11. Imrie, C. W. (2003). Prognostic indicators in acute pancreatitis. *Canadian Journal of Gastroenterology and Hepatology*, 17(5), 325-328. <https://doi.org/10.1155/2003/250815>
12. Beger, H. G., Rau, B., & Isenmann, R. (2003). Natural history of necrotizing pancreatitis. *Pancreatology*, 3(2), 93-101. <https://doi.org/10.1159/000070076>
13. Derikx, J. P., Poeze, M., van Bijnen, A. A., Buurman, W. A., & Heineman, E. (2007). Evidence for intestinal and liver epithelial cell injury in the early phase of sepsis. *Shock*, 28(5), 544-548. <https://doi.org/10.1097/shk.0b013e3180644e32>
14. Vinnik, Yu. S., Vakhrunin, A. A., Cherdantsev, D. V., & Fattakhov, V. L. (2000). Sostoyanie pecheni pri pankreonekroze i ee rol' v iskhode zabolevaniya. *Baikal'skii meditsinskii zhurnal*, 21(2), 5-9. (in Russian).
15. Chudnykh, S. M., Solov'ev, N. A., & Ivanov, Yu. V. (2001). Lechenie i profilaktika pechenochnoi nedostatochnosti pri ostrom pankreatite. *Matematicheskaya morfologiya: elektronnyi matematicheskii i mediko-biologicheskii zhurnal*, 3(4), 111-128. (in Russian).

16. Nicolas, C. T., Wang, Y., & Nyberg, S. L. (2016). Cell therapy in chronic liver disease. *Current opinion in gastroenterology*, 32(3), 189-194. <https://doi.org/10.1097/MOG.0000000000000262>
17. Shimanko, I. I., & Musselius, S. G. (1993). Ostraya pechenochnaya i pochechnaya nedostatochnost'. Moscow. (in Russian).
18. Ashrafov, A. A., Aliev, S. A., & Zeinalov, S. M. (1996). Khirurgicheskoe lechenie ostrogo pankreatita v sochetanii s konkretnymi zhelchevyvodyashchikh putei. *Khirurgiya*, 2, 12-16. (in Russian).
19. Plekhanov, A. N., & Reshetnikov, D. I. (2016). Sostoyanie portopechenochnoi gemodinamiki pri pechenochnoi nedostatochnosti u bol'nykh destruktivnym pankreatitom. *Acta Biomedica Scientifica*, 1(4 (110)), 68-71.
20. Kubyshkin, V. A., & Skoropad, V. Yu. (1989). Prichiny letal'nosti i puti ee snizheniya pri ostrom pankreatite (obzor literatury). *Khirurgiya*, 7, 138-142. (in Russian).
21. Vinnik, Yu. S., Gul'man, M. I., & Popov, V. O. (1997). Ostryi pankreatit: voprosy patogeneza, kliniki, lecheniya. Krasnoyarsk-Zelenogorsk. (in Russian).
22. Andrzejewska, A., & Dlugosz, J. (1991). Ultrastructural disorders in the liver of rats during early stages of experimental acute pancreatitis. *Poiski tegod, lekar*, 36(50-52), 990-992. (in Russian).
23. Briskin, B. S., Yatsenko, A. A., & Nazarov, V. N. (1996). Zavisimost' rezul'tatov lecheniya ostrogo pankreatita ot pravil'nosti diagnostiki stadii zabolevaniya. *Vestnik khirurgii*, 155(5), 21-24. (in Russian).
24. Fadeev, B. M., Zaitsev, A. V., & Shamsutdinov, S. M. (2004). Optimizatsiya intensivnoi terapii ostrogo destruktivnogo pankreatita. *Klinicheskaya anesteziologiya i reanimatologiya*, 1(3), 51-52. (in Russian).
25. Keleinikov, S. B., Vlasov, A. P., & Krylov, V. G. (2009). Narusheniya metabolicheskikh protsessov pri oslozhnennom ostrom pankreatite i ikh korrektsiya. *Annaly khirurg. gepatologii*, 14(1), 11. (in Russian).
26. Lutfarakhmanov, I. I., & Kakaulin, A. G. (2004). Narusheniya metabolizma i puti ikh korrektsii u bol'nykh ostrym nekrotiziruyushchim pankreatitom. In *Materialy Vserossiiskoi nauchno-metodicheskoi konferentsii* (p. 111). (in Russian).
27. Chernov, V. N. (2005). Pechochnaya nedostatochnost' pri rasprostranennom peritonite. *Annaly khirurgicheskoi gepatologii*, 10(2), 231b-231. (in Russian).
28. Plotkin, L. L., Bordunovskii, V. N., Bazarova, E. N., & Smirnov, D. M. (2008). Zashchita pecheni u bol'nykh razlitym gnoinym peritonitom, oslozhnennym sepsisom. *Anesteziologiya i reanimatologiya*, (4), 39-40. (in Russian).
29. Imaeva, A. K., Mustafin, T. I., & Sharifgaliev, I. A. (2014). Ostryi destruktivnyi pankreatit. *Baikal'skii meditsinskii zhurnal*, 131(8), 14-20. (in Russian).
30. Chalenko, V. V., & Kutushev, F. Kh. (1990). Endogennaya intoksikatsiya v khirurgii. *Vestnik khirurgii im. II Grekova*, 144(4), 3-8. (in Russian).
31. Koval'chuk, V. I., & Kostyuchenko, A. L. (1994). Neotlozhnaya pankreatologiya. St. Petersburg. (in Russian).
32. Nartailakov, M. A., Bayazitova, G. R., Mingazov, R. S., Chingizova, G. N., & Gabdrakhimov, S. R. (2009). Effektivnost' primeneniya gepatoprotektora Geptral® v kompleksnom lechenii bol'nykh s mekhanicheskoi zheltukhoi. *Ekspierimental'naya i klinicheskaya gastroenterologiya*, (8), 102-107. (in Russian).



33. Alekseev, S. A., Usovich, A. K., Antiperovich, O. F., Koshevskii, P. P., & Alekseev, D. S. (2015). Anato-mo-strukturno-morfologicheskie izmeneniya vnutrennikh organov u patsientov s destruktivnym pankreatitom. *International medical scientific journal*, 64. (in Russian).
34. Skuya I. A. (1986). *Zabolevaniya podzheludochnoi zhelezy*. Moscow. (in Russian).
35. Glumov, V. Yu., Kir'yakov, Kh. A., & Bazhenov, E. L. (1993). Ostryi peritonit: organopatologiya, pato- i tanatogenez. Izhevsk. (in Russian).
36. Mishnev, O. D., & Shchegolev A. I. (2001). *Pechen' pri endotoksikoze*. Moscow. (in Russian).
37. Plotkin, L. L. (2007). *Organnaya disfunktsiya u bol'nykh abdominal'nym sepsisom*. Chelyabinsk. (in Russian).
38. Chaplinskii, V. V., & Gnatyshak, A. I. (1971). *Ostryi pankreatit*. Moscow. (in Russian).
39. Filin, V. I., & Kostyuchenko, A. L. (1994). *Neotlozhnaya pankreatologiya*. St. Petersburg. (in Russian).
40. Gerasimenko, A. V. (2006). *Patologoanatomicheskoe obosnovanie antioksidantnoi terapii v korrektsii funktsional'nogo sostoyaniya pecheni pri ostrom pankreatite: Avtoref. dis. ... d-ra med. nauk*. Moscow. (in Russian).
41. Hofer, S., Brenner, T., Bopp, C., Steppan, J., Lichtenstern, C., Weitz, J., ... & Weigand, M. A. (2009). Cell death serum biomarkers are early predictors for survival in severe septic patients with hepatic dysfunction. *Critical care*, 13, 1-12.
42. Tarasenko, V. S., Kretinin, S. V., Obratsova, S. A., Shulanova, Zh. Zh., Basov, F. V., & Malitskaya, E. V. (2014). Opyt primeneniya preparata Gepa-Merts pri lechenii bol'nykh ostrym pankreatitom. *Meditinskii vestnik Bashkortostana*, 9(1), 38-42. (in Russian).
43. Häussinger, D. (1983). Hepatocyte heterogeneity in glutamine and ammonia metabolism and the role of an intercellular glutamine cycle during ureogenesis in perfused rat liver. *European Journal of Biochemistry*, 133(2), 269-275. <https://doi.org/10.1111/j.1432-1033.1983.tb07458.x>
44. Kawada, N., Tran-Thi, T. A., Klein, H., & Decker, K. (1993). The contraction of hepatic stellate (Ito) cells stimulated with vasoactive substances: possible involvement of endothelin 1 and nitric oxide in the regulation of the sinusoidal tonus. *European journal of biochemistry*, 213(2), 815-82. <https://doi.org/10.1111/j.1432-1033.1993.tb17824.x>
45. Eakes, A. T., Howard, K. M., Miller, J. E., & Olson, M. S. (1997). Endothelin-1 production by hepatic endothelial cells: characterization and augmentation by endotoxin exposure. *American Journal of Physiology-Gastrointestinal and Liver Physiology*, 272(3), G605-G611. <https://doi.org/10.1152/ajpgi.1997.272.3.G605>
46. Grakov, B. S., Lubenskii, Yu. M., & Nikhinson, P. A. (1992). *Metody diagnostiki i intensivnoi terapii v neotlozhnoi abdominal'noi khirurgii*. Krasnoyarsk. (in Russian).
47. Savel'ev, V. S., & Kubyshkin, V. A. (1993). *Pankreonekroz. Sostoyanie i perspektiva*. *Khirurgiya*, 6, 22-28. (in Russian).
48. Ermolov, S. Yu., Radchenko, V. G., Shabrov, A. V., & Ermolova, T. V. (2003). Disfunktsiya endoteliiya pechenochnykh gemokapillyarov: otsenka i korrektsiya gemodinamiki v terapii khronicheskikh zabolevaniy pecheni. *Disfunktsiya endoteliiya. Prichiny, mekhanizmy, farmakologicheskaya korrektsiya*. St. Petersburg, 69-82. (in Russian).
49. Panchenko, R. T., Vyrenkov, Yu. E., Yarema, I. V., & Urtaev, V. M. (1982). *Limfosorbtsiya*. Moscow. (in Russian).
50. Lefkowitz, J. H. (2016). The pathology of acute liver failure. *Advances in anatomic pathology*, 23(3), 144-158. <https://doi.org/10.1097/PAP.000000000000112>
51. Vasil'ev, I. T. (1995). *Mekhanizm razvitiya endotoksikoza pri ostrykh gnoinykh zabolevaniyakh organov bryushnoi polosti*. *Khirurgiya*, 2, 54-58. (in Russian).

52. Gavrilenko, G. A., & Tarasenko B, A. A. (1995). Lekarstvennaya zashchita pecheni do i posle operatsii na nei. *Novye tekhnologii v khirurgicheskoi gepa-tologii: Materialy*, 412-413. (in Russian).
53. Savel'ev, B. C., Buyanov, V. M., & Ognev, Yu. V. (1983). Ostryi pankreatit. Moscow. (in Russian).
54. Savel'ev, V. S., Prokubovskii, V. I., & Kubyshkin, V. A. (1984). Narusheniya tsentral'noi i regionarnoi gemodinamiki pri pankreonekroze. *Khirurgiya*, (2), 54. (in Russian).
55. Sotnichenko B. A. Posleoperatsionnyi pankreatit (voprosy etiologii, kliniki, diagnostiki, profilaktiki i lecheniya): Avtoref. dis. ... d-ra med. nauk. Khabarovsk, 1995. 48 s. (in Russian).
56. Nolan, J. P., Leibowitz, A., & Vladutic, H. (1980). The RES and pathogenesis of liver disease. *Amsterdam*, 125.
57. Moreau, R. (2016). Acute-on-chronic liver failure: a new syndrome in cirrhosis. *Clinical and molecular hepatology*, 22(1), 1. <https://doi.org/10.3350/cmh.2016.22.1.1>
58. Podymova, S. D. (1993). Zabolevaniya pecheni. Moscow. (in Russian).
59. Shulutko, B. I. (1993). Zabolevaniya pecheni i pochek. St. Petersburg. (in Russian).
60. Shugaev, A. I., & Zinevich, V. P. (1989). Endogennaya intoksikatsiya pri ostrom pankreatite. *Vestnik khirurgii im. II Grekova*, (3), 126. (in Russian).
61. Hong, Y. S., Sinn, D. H., Gwak, G. Y., Cho, J., Kang, D., Paik, Y. H., ... & Paik, S. W. (2016). Characteristics and outcomes of chronic liver disease patients with acute deteriorated liver function by severity of underlying liver disease. *World Journal of Gastroenterology*, 22(14), 3785. <https://doi.org/10.3748/wjg.v22.i14.3785>
62. Filin, V. I. (1982). Ostrye zabolevaniya i povrezhdeniya podzheludochnoi zhelezy. Moscow. (in Russian).
63. Shurkalin, B. K., Gorskii, V. A., & Lindenberg, A. A. (1986). Sindrom endogennoi intoksikatsii pri pankreonekroze. *Klinicheskaya meditsina*, (8), 15-18. (in Russian).
64. Savel'ev, V. S., Kubyshkin, V. A., & Kazantsev, G. B. (2000). Rol' prognozirovaniya techeniya pankreonekroza v vybore lechebnoi taktiki. *Khirurgiya*, (9), 72-79. (in Russian).
65. Savel'ev, V. S., Buyanov, V. M., Kubyshkin, V. A., & Zhadkevich, M. M. (1981). Prognozirovanie techeniya ostrogo pankreatita. *Khirurgiya*, (10), 47-51. (in Russian).
66. Vidmaier, U., Rau, B., & Beger, G. (1997). Khirurgicheskoe lechenie pankreonekroza. *Annaly khirurgicheskoi gepatologii*, 2(2), 47. (in Russian).
67. Zhang, F. H., Sun, Y. H., Fan, K. L., Dong, X. B., Han, N., Zhao, H., & Kong, L. (2017). Protective effects of heme oxygenase-1 against severe acute pancreatitis via inhibition of tumor necrosis factor- $\alpha$  and augmentation of interleukin-10. *BMC gastroenterology*, 17, 1-7. <https://doi.org/10.1186/s12876-017-0651-4>
68. Boxhoorn, L., Voermans, R. P., Bouwense, S. A., Bruno, M. J., Verdonk, R. C., Boermeester, M. A., van Santvoort, H. C., & Besselink, M. G. (2020). Acute pancreatitis. *Lancet*, 5 (396(10252)), 726-734. [https://doi.org/10.1016/S0140-6736\(20\)31310-6](https://doi.org/10.1016/S0140-6736(20)31310-6)
69. Windsor, J. A., Fearon, K. C. H., Ross, J. A., Barclay, G. R., Smyth, E., Poxton, I., & Carter, D. C. (1993). Role of serum endotoxin and antiendotoxin core antibody levels in predicting the development of multiple organ failure in acute pancreatitis. *Journal of British Surgery*, 80(8), 1042-1046. <https://doi.org/10.1002/bjs.1800800840>
70. Chen, T., Ye, X., Huang, Z., Chen, R., Zhuge, X., Chen, X., & Du, Y. (2012). Fgl2 prothrombinase is involved in severe acute pancreatitis-associated liver injury. *Hepato-gastroenterology*, 59(116), 1225-1229. <https://doi.org/10.5754/hge12117>
71. Mayer, J., Rau, B., Gansauge, F., & Beger, H. G. (2000). Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications. *Gut*, 47(4), 546-552.

72. Brivet, F. G., Emilie, D., & Galanaud, P. (1999). Pro-and anti-inflammatory cytokines during acute severe pancreatitis: an early and sustained response, although unpredictable of death. *Critical care medicine*, 27(4), 749-755.
73. Xu, X., Ai, F., & Huang, M. (2020). Deceased serum bilirubin and albumin levels in the assessment of severity and mortality in patients with acute pancreatitis. *International journal of medical sciences*, 17(17), 2685. <https://doi.org/10.7150/ijms.49606>
74. Iurlaro, R., & Muñoz-Pinedo, C. (2016). Cell death induced by endoplasmic reticulum stress. *The FEBS journal*, 283(14), 2640-2652.
75. Wang, X., Eno, C. O., Altman, B. J., Zhu, Y., Zhao, G., Olberding, K. E., ... & Li, C. (2011). ER stress modulates cellular metabolism. *Biochemical Journal*, 435(1), 285-296. <https://doi.org/10.1042/BJ20101864>
76. Hou, S., Tang, X., Cui, H., Liu, C., Bai, X., Shi, L., & Shi, Y. (2019). Fatty liver disease is associated with the severity of acute pancreatitis: A systematic review and meta-analysis. *International Journal of Surgery*, 65, 147-153. <https://doi.org/10.1016/j.ijssu.2019.04.003>
77. Liu, W., Du, J. J., Li, Z. H., Zhang, X. Y., & Zuo, H. D. (2021). Liver injury associated with acute pancreatitis: The current status of clinical evaluation and involved mechanisms. *World journal of clinical cases*, 9(34), 10418. <https://doi.org/10.12998/wjcc.v9.i34.10418>

#### Список литературы:

1. Гельфанд Б. Р., Филимонов М. И., Бурневич С. З. Абдоминальный сепсис // Русский медицинский журнал. 1998. №11. С. 3.
2. Howes N., Greenhalf W., Rutherford S., O'Donnell M., Mountford R., Ellis I., Neoptolemos J. P. A new polymorphism for the RI22H mutation in hereditary pancreatitis // Gut. 2001. V. 48. №2. P. 247-250. <https://doi.org/10.1136/gut.48.2.247>
3. Werner J., Hartwig W., Uhl W., Müller C., Büchler M. W. Useful markers for predicting severity and monitoring progression of acute pancreatitis // Pancreatology. 2003. V. 3. №2. P. 115-127. <https://doi.org/10.1159/000070079>
4. Шугаев А. И., Гера И. Н., Мосоян С. С., Алиев А. Я., Папшева В. В. Факторы, определяющие развитие гнойных осложнений острого панкреатита в реактивной фазе // Вестник хирургии имени ИИ Грекова. 2009. Т. 168. №1. С. 54-56.
5. Савельев В. С., Филимонов М. И., Гельфанд Б. Р., Бурневич С. З. Деструктивный панкреатит: алгоритм диагностики и лечения // Consilium medicum. 2001. Т. 3. №6. С. 273-279.
6. Гальперин Э. И., Дюжева Т. Г. Панкреонекроз: неиспользованные резервы лечения (Дискуссионные вопросы к круглому столу) // Анналы хирургической гепатологии. 2007. Т. 12. №2. С. 46-51.
7. Нартайлаков М. А., Гвоздик Т. П., Ткаченко В. Н., Кононов В. С. Коррекция печеночной недостаточности в комплексном лечении больных с инфицированным панкреонекрозом // Медицинский вестник Башкортостана. 2010. Т. 5. №5. С. 6-10.
8. Пропп А. Р., Полуэктов В. Л., Лобанов В. Г., Арестович Р. А., Пранкевич Н. Н., Астанков Р. А., Кузьменко В. В. Технические решения при устранении протоковой гипертензии поджелудочной железы // Хирургия. Журнал им. НИ Пирогова. 2011. №6. С. 32-37.
9. Тимербулатов В. М., Мустафин Т. И., Тимербулатов М. В., Имаева А. К. Сравнительный анализ балльной оценки тяжести острого панкреатита // Вестник хирургии имени ИИ Грекова. 2008. Т. 167. №2. С. 79-81.

10. Гельфанд Е. Б., Гологорский В. А., Гельфанд Б. Р. Клиническая характеристика абдоминального сепсиса у хирургических больных // Инфекции и антимикробная терапия. 2000. Т. 1. №1. С. 6.
11. Imrie C. W. Prognostic indicators in acute pancreatitis // Canadian Journal of Gastroenterology and Hepatology. 2003. V. 17. №5. P. 325-328. <https://doi.org/10.1155/2003/250815>
12. Beger H. G., Rau B., Isenmann R. Natural history of necrotizing pancreatitis // Pancreatology. 2003. V. 3. №2. P. 93-101. <https://doi.org/10.1159/000070076>
13. Derikx J. P., Poeze M., van Bijnen A. A., Buurman W. A., Heineman E. Evidence for intestinal and liver epithelial cell injury in the early phase of sepsis // Shock. 2007. V. 28. №5. P. 544-548. <https://doi.org/10.1097/shk.0b013e3180644e32>
14. Винник Ю. С., Вахрунин А. А., Черданцев Д. В., Фаттахов В. Л. Состояние печени при панкреонекрозе и ее роль в исходе заболевания // Байкальский медицинский журнал. 2000. Т. 21. №2. С. 5-9.
15. Чудных С. М., Соловьев Н. А., Иванов Ю. В. Лечение и профилактика печеночной недостаточности при остром панкреатите // Математическая морфология: электронный математический и медико-биологический журнал. 2001. Т. 3. №4. С. 111-128.
16. Nicolas C. T., Wang Y., Nyberg S. L. Cell therapy in chronic liver disease // Current opinion in gastroenterology. 2016. V. 32. №3. P. 189-194. <https://doi.org/10.1097/MOG.0000000000000262>
17. Шиманко И. И., Мусселиус С. Г. Острая печеночная и почечная недостаточность. М.: Медицина, 1993. 288 с.
18. Ашрафов А. А., Алиев С. А., Зейналов С. М. Хирургическое лечение острого панкреатита в сочетании с конкрементами желчевыводящих путей // Хирургия. 1996. Т. 2. С. 12-16.
19. Плеханов А. Н., Решетников Д. И. Состояние портопечёночной гемодинамики при печёночной недостаточности у больных деструктивным панкреатитом // Acta Biomedica Scientifica. 2016. Т. 1. №4 (110). С. 68-71.
20. Кубышкин В. А., Скоропад В. Ю. Причины летальности и пути ее снижения при остром панкреатите (обзор литературы) // Хирургия. 1989. Т. 7. С. 138-142.
21. Винник Ю. С., Гульман М. И., Попов В. О. Острый панкреатит: вопросы патогенеза, клиники, лечения. Красноярск-Зеленогорск, 1997. 208 с.
22. Andrzejewska A. et al. Ultrastructural disorders in the liver of rats during early stages of experimental acute pancreatitis // Poiski tegod, lekar. 1991. V. 36. №50-52. P. 990-992.
23. Брискин Б. С., Яценко А. А., Назаров В. Н. Зависимость результатов лечения острого панкреатита от правильности диагностики стадий заболевания // Вестник хирургии. 1996. Т. 155. №5. С. 21-24.
24. Фадеев Б. М., Зайцев А. В., Шамсутдинов С. М. Оптимизация интенсивной терапии острого деструктивного панкреатита // Клиническая анестезиология и реаниматология. 2004. Т. 1. №3. С. 51-52.
25. Келейников С. Б., Власов А. П., Крылов В. Г. Нарушения метаболических процессов при осложненном остром панкреатите и их коррекция // Анналы хирург. гепатологии. 2009. Т. 14. №1. С. 11.
26. Лутфарахманов И. И., Какаулин А. Г. Нарушения метаболизма и пути их коррекции у больных острым некротизирующим панкреатитом // Материалы Всероссийской научно-методической конференции. 2004. С. 111.

27. Чернов В. Н. Печеночная недостаточность при распространенном перитоните // *Анналы хирургической гепатологии*. 2005. Т. 10. №2. С. 231b-231.
28. Плоткин Л. Л., Бордуновский В. Н., Базарова Е. Н., Смирнов Д. М. Защита печени у больных разлитым гнойным перитонитом, осложненным сепсисом // *Анестезиология и реаниматология*. 2008. №4. С. 39-40.
29. Имаева А. К., Мустафин Т. И., Шарифгалиев И. А. Острый деструктивный панкреатит // *Байкальский медицинский журнал*. 2014. Т. 131. №8. С. 14-20.
30. Чаленко В. В., Кутушев Ф. Х. Эндогенная интоксикация в хирургии // *Вестник хирургии им. ИИ Грекова*. 1990. Т. 144. №4. С. 3-8.
31. Ковальчук В. И., Костюченко А. Л. Неотложная панкреатология. СПб.: Питер, 1994. 416 с.
32. Нартайлаков М. А., Баязитова Г. Р., Мингазов Р. С., Чингизова Г. Н., Габдрахимов С. Р. Эффективность применения гепатопротектора Гептрал® в комплексном лечении больных с механической желтухой // *Экспериментальная и клиническая гастроэнтерология*. 2009. №8. С. 102-107.
33. Алексеев С. А., Усович А. К., Антиперович О. Ф., Кошевский П. П., Алексеев Д. С. Анатомо-структурно-морфологические изменения внутренних органов у пациентов с деструктивным панкреатитом // *International medical scientific journal*. 2015. С. 64.
34. Скуя И. А. Заболевания поджелудочной железы. М.: Медицина, 1986. 238 с.
35. Глумов В. Ю., Кирьяков Х. А., Баженов Е. Л. Острый перитонит: органопатология, пато- и танатогенез. Ижевск, 1993. 181 с.
36. Мишнев О. Д., Щеголев А. И. Печень при эндотоксикозе. М.: РАМН, 2001. 236 с.
37. Плоткин Л. Л. Органная дисфункция у больных абдоминальным сепсисом. Челябинск, 2007. 531 с.
38. Чаплинский В. В., Гнатышак А. И. Острый панкреатит. М., 1971. 86 с.
39. Филин В. И., Костюченко А. Л. Неотложная панкреатология. СПб.: Питер, 1994. 416 с.
40. Герасименко А. В. Патологоанатомическое обоснование антиоксидантной терапии в коррекции функционального состояния печени при остром панкреатите: Автореф. дис. ... д-ра мед. наук. М., 2006. 36 с.
41. Hofer S., Brenner T., Vopp C., Steppan J., Lichtenstern C., Weitz J., Weigand M. A. Cell death serum biomarkers are early predictors for survival in severe septic patients with hepatic dysfunction // *Critical care*. 2009. V. 13. P. 1-12. <https://doi.org/10.1186/cc7923>
42. Тарасенко В. С., Кретинин С. В., Образцова С. А., Шуланова Ж. Ж., Басов Ф. В., Малицкая Е. В. Опыт применения препарата Гепта-Мерц при лечении больных острым панкреатитом // *Медицинский вестник Башкортостана*. 2014. Т. 9. №1. С. 38-42.
43. Häussinger D. Hepatocyte heterogeneity in glutamine and ammonia metabolism and the role of an intercellular glutamine cycle during ureogenesis in perfused rat liver // *European Journal of Biochemistry*. 1983. V. 133. №2. P. 269-275. <https://doi.org/10.1111/j.1432-1033.1983.tb07458.x>
44. Kawada N., Tran-Thi T. A., Klein H., Decker K. The contraction of hepatic stellate (Ito) cells stimulated with vasoactive substances: possible involvement of endothelin 1 and nitric oxide in the regulation of the sinusoidal tonus // *European journal of biochemistry*. 1993. V. 213. №2. P. 815-823. <https://doi.org/10.1111/j.1432-1033.1993.tb17824.x>
45. Eakes A. T., Howard K. M., Miller J. E., Olson M. S. Endothelin-1 production by hepatic endothelial cells: characterization and augmentation by endotoxin exposure // *American Journal of Physiology-Gastrointestinal and Liver Physiology*. 1997. V. 272. №3. P. G605-G611. <https://doi.org/10.1152/ajpgi.1997.272.3.G605>

46. Граков Б. С., Лубенский Ю. М., Нихинсон П. А. Методы диагностики и интенсивной терапии в неотложной абдоминальной хирургии. Красноярск, 1992. 240 с.
47. Савельев В. С., Кубышкин В. А. Панкреонекроз. Состояние и перспектива // Хирургия. 1993. Т. 6. С. 22-28.
48. Ермолов С. Ю., Радченко В. Г., Шабров А. В., Ермолова Т. В. Дисфункция эндотелия печеночных гемокапилляров: оценка и коррекция гемодинамики в терапии хронических заболеваний печени // Дисфункция эндотелия. Причины, механизмы, фармакологическая коррекция/под ред. НН Петрищева.-СПб.: Изд-во СПбГМУ. 2003. С. 69-82.
49. Панченко Р. Т., Выренков Ю. Е., Ярема И. В., Уртаев В. М. Лимфосорбция. М.: Медицина, 1982. 240 с.
50. Lefkowitz J. H. The pathology of acute liver failure // Advances in anatomic pathology. 2016. V. 23. №3. P. 144-158. <https://doi.org/10.1097/PAP.000000000000112>
51. Васильев И. Т. Механизм развития эндотоксикоза при острых гнойных заболеваниях органов брюшной полости // Хирургия. 1995. Т. 2. С. 54-58.
52. Гавриленко Г. А., Тарасенко В. С. А. А. Лекарственная защита печени до и после операций на ней // Новые технологии в хирургической гепатологии: Материалы. 1995. С. 412-413.
53. Савельев В. С., Буянов В. М., Огнев Ю. В. Острый панкреатит. М.: Медицина, 1983. 240 с.
54. Савельев В. С., Прокубовский В. И., Кубышкин В. А. Нарушения центральной и регионарной гемодинамики при панкреонекрозе // Хирургия. 1984. №2. С. 54.
55. Сотниченко Б. А. Послеоперационный панкреатит (вопросы этиологии, клиники, диагностики, профилактики и лечения): Автореф. дис. ... д-ра мед. наук. Хабаровск, 1995. 48 с.
56. Nolan J. P., Leibowitz A., Vladutic H. The RES and pathogenesis of liver disease // Amsterdam. 1980. P. 125.
57. Moreau R. Acute-on-chronic liver failure: a new syndrome in cirrhosis // Clinical and molecular hepatology. 2016. V. 22. №1. P. 1. <https://doi.org/10.3350/cmh.2016.22.1.1>
58. Подымова С. Д. Заболевания печени. М.: Медицина, 1993. 544 с.
59. Шулуто Б. И. Заболевания печени и почек. СПб., 1993. 479 с.
60. Шугаев А. И., Зиневич В. П. Эндогенная интоксикация при остром панкреатите // Вестник хирургии им. ИИ Грекова. 1989. №3. С. 126.
61. Hong Y. S., Sinn D. H., Gwak G. Y., Cho J., Kang D., Paik Y. H., Paik S. W. Characteristics and outcomes of chronic liver disease patients with acute deteriorated liver function by severity of underlying liver disease // World Journal of Gastroenterology. 2016. V. 22. №14. P. 3785. <https://doi.org/10.3748/wjg.v22.i14.3785>
62. Филин В. И. Острые заболевания и повреждения поджелудочной железы Л.: Медицина, 1982. 245 с.
63. Шуркалин Б. К., Горский В. А., Линденберг А. А. Синдром эндогенной интоксикации при панкреонекрозе // Клиническая медицина. 1986. №8. С. 15-18.
64. Савельев В. С., Кубышкин В. А., Казанцев Г. Б. Роль прогнозирования течения панкреонекроза в выборе лечебной тактики // Хирургия. 2000. №9. С. 72-79.
65. Савельев В. С., Буянов В. М., Кубышкин В. А., Жадкевич М. М. Прогнозирование течения острого панкреатита // Хирургия. 1981. №10. С. 47-51.
66. Видмайер У., Рау Б., Бегер Г. Хирургическое лечение панкреонекроза // Анналы хирургической гепатологии. 1997. Т. 2. №2. С. 47.

67. Zhang F. H., Sun Y. H., Fan K. L., Dong X. B., Han N., Zhao H., Kong L. Protective effects of heme oxygenase-1 against severe acute pancreatitis via inhibition of tumor necrosis factor- $\alpha$  and augmentation of interleukin-10 // BMC gastroenterology. 2017. V. 17. P. 1-7. <https://doi.org/10.1186/s12876-017-0651-4>
68. Boxhoorn L., Voermans R. P., Bouwense S. A., Bruno M. J., Verdonk R. C., Boermeester M. A., van Santvoort H. C., Besselink M. G. Acute pancreatitis // Lancet. 2020. №5. V. 396. №10252. P. 726-734. [https://doi.org/10.1016/S0140-6736\(20\)31310-6](https://doi.org/10.1016/S0140-6736(20)31310-6)
69. Windsor J. A., Fearon K. C. H., Ross J. A., Barclay G. R., Smyth E., Poxton I., Carter D. C. Role of serum endotoxin and antiendotoxin core antibody levels in predicting the development of multiple organ failure in acute pancreatitis // Journal of British Surgery. 1993. V. 80. №8. P. 1042-1046. <https://doi.org/10.1002/bjs.1800800840>
70. Chen T., Ye X., Huang Z., Chen R., Zhuge X., Chen X., Du Y. Fgl2 prothrombinase is involved in severe acute pancreatitis-associated liver injury // Hepato-gastroenterology. 2012. V. 59. №116. P. 1225-1229. <https://doi.org/10.5754/hge12117>
71. Mayer J., Rau B., Gansauge F., Beger H. G. Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications // Gut. 2000. V. 47. №4. P. 546-552.
72. Brivet F. G., Emilie D., Galanaud P. Pro- and anti-inflammatory cytokines during acute severe pancreatitis: an early and sustained response, although unpredictable of death // Critical care medicine. 1999. V. 27. №4. P. 749-755.
73. Xu X., Ai F., Huang M. Deceased serum bilirubin and albumin levels in the assessment of severity and mortality in patients with acute pancreatitis // International journal of medical sciences. 2020. V. 17. №17. P. 2685. <https://doi.org/10.7150/ijms.49606>
74. Iurlaro R., Muñoz-Pinedo C. Cell death induced by endoplasmic reticulum stress // The FEBS journal. 2016. V. 283. №14. P. 2640-2652.
75. Wang X., Eno C. O., Altman B. J., Zhu Y., Zhao G., Olberding K. E., Li C. ER stress modulates cellular metabolism // Biochemical Journal. 2011. V. 435. №1. P. 285-296. <https://doi.org/10.1042/BJ20101864>
76. Hou S., Tang X., Cui H., Liu C., Bai X., Shi L., Shi Y. Fatty liver disease is associated with the severity of acute pancreatitis: A systematic review and meta-analysis // International Journal of Surgery. 2019. V. 65. P. 147-153. <https://doi.org/10.1016/j.ijssu.2019.04.003>
77. Liu W., Du J. J., Li Z. H., Zhang X. Y., Zuo H. D. Liver injury associated with acute pancreatitis: The current status of clinical evaluation and involved mechanisms // World journal of clinical cases. 2021. V. 9. №34. P. 10418. <https://doi.org/10.12998/wjcc.v9.i34.10418>

Работа поступила  
в редакцию 14.10.2024 г.

Принята к публикации  
22.10.2024 г.

Ссылка для цитирования:

Kozhakhmetov S., Rustemova K., Tsoi O., Aknazarov K., Zhalgasbaev Zh., Osmonaliev K. Hepatic Failure in Pancreonecrosis and the Development of Abdominal Sepsis // Бюллетень науки и практики. 2024. Т. 10. №11. С. 181-195. <https://doi.org/10.33619/2414-2948/108/24>

Cite as (APA):

Kozhakhmetov, S., Rustemova, K., Tsoi, O., Aknazarov, K., Zhalgasbaev, Zh. & Osmonaliev, K. (2024). Hepatic Failure in Pancreonecrosis and the Development of Abdominal Sepsis. *Bulletin of Science and Practice*, 10(11), 181-195. <https://doi.org/10.33619/2414-2948/108/24>